Global Artificial Intelligence in Cancer Diagnostics Market Size study & Forecast, by Component (Software Solutions, Hardware, Services), by Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others), by End User (Ho

Global Artificial Intelligence in Cancer Diagnostics Market Size study & Forecast, by Component (Software Solutions, Hardware, Services), by Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others), by End User (Hospital, Surgical Centers and Medical Institutes, Others), and Regional Analysis, 2023-2030

Global Artificial Intelligence in Cancer Diagnostics Market is valued at approximately USD 137.8 million in 2022 and is anticipated to grow with a healthy growth rate of more than 26.3% over the forecast period 2023-2030. Artificial Intelligence in Cancer Diagnostics refers to applying AI algorithms to analyze the medical data of users to detect cancer and help in treating it at an early stage. The Artificial Intelligence in Cancer Diagnostics Market is expanding because of factors such as a rise in healthcare expenditure, an increase in popularity for early detection of diseases and a shortage of healthcare professionals. However, data protection concerns of people using the technology and data inconsistency and flaws in the algorithm of AI tend to lower the market growth.

The rise in health care expenditure is a factor driving Artificial Intelligence In Cancer Diagnostics Market . According to health affairs 2023, health expenditures are predicted to grow 5.4%, in 2022–31 and to account for roughly 20% of the economy by the end of that period. The increase in popularity for early detection of diseases is another driving this market as people are now more concerned about their health and they want to detect every disease at an early stage as early detection of disease leads to easy and fast treatment of that disease moreover shortage of health care professionals has led the AI market to grow in the health care sector. An increase in cancer cases is an opportunity for this market to grow as according to Cancer Research UK 2023 it is estimated that there be 28 million new cancer cases globally each year by 2040. Another opportunity for this market to expand is a rise in technological advancement according to Statista 2023, in 2022, spending on digital transformation is estimated to reach USD 1.6 trillion. By 2026, global digital transformation spending is forecast to reach USD 3.4 trillion.

The key regions considered for the Global Artificial Intelligence in Cancer Diagnostics Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rise in the advancement of technology in the healthcare sector, the presence of market players in this region and growing cancer cases coupled with growing digital transformation has led to the growth of the market in this region. Asia Pacific is expected to grow significantly over the forecast period, owing to factors such as government initiatives in the healthcare sector and the rise in popularity of AI-based cancer diagnostic technologies.

Major market player included in this report are:
Medial EarlySign Ltd.
Cancer Center.ai
Microsoft Corporation
Flatiron Health
PATHAI, INC.
Google Deep Mind
Tempus Labs, Inc.
Oncora Medical
Whiterabbit.ai
Ibex Medical Analytics

Recent Developments in the Market:
 In May 2023, EarlySign, a cutting-edge business creating AI-based clinical predictive analytics announced a collaboration with Roche, it enable Roche Diagnostics to include EarlySign ColonFlag in its navify algorithm Suite. ColonFlag signifies a continuation of growth for the navify portfolio of digital solutions and expands on the collaborations between EarlySign and Roche to promote early diagnosis of stomach and lung cancer.
 In June 2023, Tempus launched the Standalone RNA Sequencing Test, xR. A Tempus xR is made for solid tumors and is a transcriptome panel. That detects aberrant splicing for MET Exon 14 and EGFRvIII as well as clinically significant combination of 100 targeted genes.

Global Artificial Intelligence in Cancer Diagnostics Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Component, Cancer, End User Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Component:
Software Solutions
Hardware
Services

By Cancer Type:
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Brain Tumor
Others

By End User:
Hospital
Surgical Centers and Medical Institutes
Others

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Medial EarlySign Ltd.
Cancer Center.ai
Microsoft Corporation
Flatiron Health
PATHAI, INC.
Google Deep Mind
Tempus Labs, Inc.
Oncora Medical
Whiterabbit.ai
Ibex Medical Analytics

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.